Comparative pharmacokinetics of danofloxacin in healthy and<i>Pasteurella multocida</i>infected ducks

Xiao, Xia; Lan, Weixuan; Wang, Ying; Jiang, Lijie; Jiang, Yongjia; Wang, Zhiqiang

doi:10.1111/jvp.12712

Cited by 17 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the lower ClT/F of danofloxacin in the ID (0.38 L/h•kg) and IDM (0.28 L/h•kg) groups than that in the HD (0.45 L/h•kg) and HDM (0.32 L/h•kg) groups indicates the effect of infection. These findings are consistent with other studies that reported a reduced ClT/F of danofloxacin, marbofloxacin, and tilmicosin in respiratory infections [69][70][71][72]. However, the ClT/F of marbofloxacin increased in lambs naturally infected with M. haemolytica [73].…”

Section: Pharmacokinetics Of Danofloxacinsupporting

confidence: 92%

Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections

Ural

Üney

2021

Antibiotics

View full text Add to dashboard Cite

The aim of this study was to determine the pharmacokinetics and pharmacodynamics of danofloxacin (DAN; 6 mg/kg) following subcutaneous administration alone or co-administration with meloxicam (MLX; 1 mg/kg) in healthy lambs and lambs with respiratory infections. The study was carried out using a total of four groups: HD (healthy; n = 6) and ID (infected; n = 7) groups who were administered DAN only, and HDM (healthy; n = 6) and IDM (infected; n = 7) groups who were administered DAN and MLX simultaneously. The plasma concentrations of DAN were determined using high-performance liquid chromatography–UV and analyzed by the non-compartmental method. DAN exhibited a similar elimination half-life in all groups, including both the healthy and infected lambs. The total clearance in the HDM, ID and IDM groups and volume of distribution in the HDM and IDM groups were significantly reduced. MLX in the IDM group significantly increased the area under the curve (AUC) and peak concentration (Cmax) of DAN compared to the HD group. The Mannheimia haemolytica, Escherichia coli, and Streptococcus spp. strains were isolated from bronchoalveolar lavage fluid samples of the infected lambs. When co-administration with meloxicam, DAN at a 6 mg/kg dose can provide optimum values of ƒAUC0–24/MIC (>56 h) and ƒCmax/MIC (>8) for susceptible M. haemolytica isolates with an MIC90 value of 0.25 µg/mL and susceptible E. coli isolates with an MIC value of ≤0.125 µg/mL.

show abstract

Section: Pharmacokinetics Of Danofloxacinsupporting

confidence: 92%

Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections

Ural

Üney

2021

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Clinical symptoms and pathological changes were monitored using standard techniques. Bacteria isolated from liver and lung were cultured using MHA plates and identified by light microscopy after Wright–Giemsa staining to examine P. multocida as previously described (Xiao et al., ). The disease model was chosen when (a) animals showed the typical clinical symptoms and pathological changes; (b) P. multocida was isolated from liver and lung tissues; and (c) animals survived more than 36 hr.…”

Section: Methodsmentioning

confidence: 99%

Comparative pharmacokinetics of florfenicol in healthy and Pasteurella multocida‐infected Gaoyou ducks

Lan

Xiao

Jiang

et al. 2019

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

Pasteurella multocida is the causative agent of fowl cholera, and florfenicol (FF) has potent antibacterial activity against P. multocida and is widely used in the poultry industry. In this study, we established a P. multocida infection model in ducks and studied the pharmacokinetics of FF in serum and lung tissues after oral administration of 30 mg/kg bodyweight. The maximum concentrations reached (Cmax) were lower in infected ducks (13.88 ± 2.70 μg/ml) vs. healthy control animals (17.86 ± 1.57 μg/ml). In contrast, the mean residence time (MRT: 2.35 ± 0.13 vs. 2.27 ± 0.18 hr) and elimination half‐life (T½β: 1.63 ± 0.08 vs. 1.57 ± 0.12 hr) were similar for healthy and diseased animals, respectively. As a result, the area under the concentration curve for 0–12 hr (AUC0–12 hr) for FF in healthy ducks was significantly greater than that in infected ducks (49.47 ± 5.31 vs. 34.52 ± 8.29 μg hr/ml). The pharmacokinetic differences of FF in lung tissues between the two groups correlated with the serum pharmacokinetic differences. The Cmax and AUC0–12 hr values of lung tissue in healthy ducks were higher than those in diseased ducks. The concentration of FF in lung tissues was approximately 1.2‐fold higher than that in serum both in infected and healthy ducks indicating that FF is effective in treating respiratory tract infections in ducks.

show abstract

“…Consistently, the PK of danofloxacin in healthy and Pasteurella multocida infected ducks (both in serum and lung tissues) were different for both ducks (Xiao et al, ) and chickens (Zeng et al, ). The CL β / F was lower in infected ducks, and the T1/2β was also prolonged in infected animals, which means that the clearance and elimination rate of danofloxacin were slower in infected animals.…”

Section: Discussionmentioning

confidence: 81%

“…The CL β / F was lower in infected ducks, and the T1/2β was also prolonged in infected animals, which means that the clearance and elimination rate of danofloxacin were slower in infected animals. Besides, the total amount of drug (AUCs) in the circulation was increased in the Pasteurella multocida infected ducks, and the distribution rate of danofloxacin was slower in healthy ducks than in infected ducks (Xiao et al, ).…”

Section: Discussionmentioning

confidence: 99%

Population pharmacokinetics for danofloxacin in the intestinal contents of healthy and infected chickens

Tian

Chen

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Avian pathogenic Escherichia coli could cause localized and systemic infection in the poultry, and danofloxacin is usually used to treat avian colibacillosis through oral administration. To promote prudent use of danofloxacin and reduce the emergence of drug‐resistant E. coli strains, it is necessary to understand the population pharmacokinetics (PopPK) of danofloxacin in chicken intestines. In this study, reversed‐phase high performance liquid chromatography (HPLC) with fluorescence detection was used to detect the concentrations of danofloxacin in the contents of duodenum, jejunum, and ileum of the healthy and infected chickens after single oral administration (5 mg/kg body weight). Then, the PopPK of danofloxacin in intestines were analyzed using NONMEM software. As a result, a two‐compartment PK model best described the time‐concentration profile of duodenal, jejunal, and ileal contents. Interestingly, absorption rate (Ka), distribution volume (V), and clearance (CL) for danofloxacin from duodenal, jejunal to ileal contents were sequentially decreased in the healthy chickens. However, the trend of Ka, V, and CL of danofloxacin was changed dramatically in the intestine of infected chickens. Ka and V of danofloxacin in the jejunum were higher than in the ileum and duodenum. Compared with healthy chickens, Ka and V of danofloxacin in the duodenum decreased significantly, while increased in jejunum, respectively. It has been noted that Ka decreased and V increased in the ileum of infected chickens. Besides, CL in the duodenum, jejunum, and ileum of infected chickens was, respectively, lower than those of healthy chickens. Interestingly, the relative bioavailability (F) of danofloxacin in the ileum was relatively higher in both healthy and infected chickens. In addition, F in the duodenal, jejunal, and ileal contents of infected chickens was respectively higher than healthy chickens. In summary, the PopPK for danofloxacin in infected chicken intestines was quite different from healthy chickens. The absorption, distribution, and clearance of danofloxacin in healthy chickens decreased from duodenum to jejunum and to ileum. Moreover, the pharmacokinetic characteristics in the intestine of infected chickens changed significantly, and the pharmacokinetic characteristics in the ileum can be used as a representative of all intestinal segments.

show abstract

Comparative pharmacokinetics of danofloxacin in healthy andPasteurella multocidainfected ducks

Cited by 17 publications

References 25 publications

Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections

Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections

Comparative pharmacokinetics of florfenicol in healthy and Pasteurella multocida‐infected Gaoyou ducks

Population pharmacokinetics for danofloxacin in the intestinal contents of healthy and infected chickens

Contact Info

Product

Resources

About